VC View: Deal-Making During A Pandemic And 2021 Expectations
Interview With Naseem Amin And Christian Schetter
Executive Summary
In the latest instalment of VC Playbook, In Vivo gets to know Arix Bioscience, a relatively young venture capital firm that went public in 2016. Arix has “has many similarities yet some key differences from a typical venture capital firm,” says the management team.